FibroGen Inc (FGEN) Stock Analysis

FibroGen Inc (FGEN) is a publicly traded company in the HEALTHCARE sector. It trades at $9.71. This page summarizes the public market data, fundamentals, and frequently asked questions for FGEN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $9.71

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company based in San Francisco, California, dedicated to developing and commercializing innovative therapies aimed at addressing significant unmet medical needs. Specializing in treatments for anemia associated with chronic kidney disease and fibrotic diseases, FibroGen utilizes its proprietary technology platforms to pioneer novel therapeutics that enhance patient outcomes. The company strategically positions itself within the biopharmaceutical landscape...

GNG Research Analysis

GNG Research scores FibroGen Inc (FGEN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FGEN.

Frequently Asked Questions

Does FGEN pay dividends?

FibroGen Inc (FGEN) does not currently pay a regular dividend.